Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Stomach Neoplasms × anlotinib × Clear all

Phase

Phase 2 4 Phase NA 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5 Sarcoma 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Ovarian Neoplasms 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Gynecological Cancer 1 Glioblastoma 1 Craniopharyngioma 1 Carcinoma, Hepatocellular 1 Anlotinib 1 Adenocarcinoma of Lung 1

Interventions

pembrolizumab 23 Paclitaxel 22 Oxaliplatin 16 Nivolumab 15 Capecitabine 13 Docetaxel 12 Cisplatin 12 S 1 (combination) 10 Irinotecan 9 Fluorouracil 8 Cyclophosphamide 8 Carboplatin 8 fludarabine 7 Trastuzumab 7 tislelizumab 6 aldesleukin 5 Ramucirumab 5 Drug Therapy 5 apatinib 4 Radiotherapy 4 Leucovorin 4 Interleukin-2 4 Gemcitabine 4 Bevacizumab 4 sintilimab 3 regorafenib 3 olaparib 3 Pemetrexed 3 Ipilimumab 3 Immunotherapy, Adoptive 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04963088 2025-06-26

TALENT

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡